TRANSMEDICS GROUP INC (TMDX) Fundamental Analysis & Valuation

NASDAQ:TMDX • US89377M1099

Current stock price

113.59 USD
+0.38 (+0.34%)
Last:

This TMDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. TMDX Profitability Analysis

1.1 Basic Checks

  • TMDX had positive earnings in the past year.
  • In the past year TMDX had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TMDX reported negative net income in multiple years.
  • In multiple years TMDX reported negative operating cash flow during the last 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.81%, TMDX belongs to the top of the industry, outperforming 97.83% of the companies in the same industry.
  • TMDX's Return On Equity of 40.22% is amongst the best of the industry. TMDX outperforms 98.91% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.76%, TMDX belongs to the top of the industry, outperforming 85.87% of the companies in the same industry.
  • TMDX had an Average Return On Invested Capital over the past 3 years of 4.27%. This is below the industry average of 9.18%.
  • The 3 year average ROIC (4.27%) for TMDX is below the current ROIC(8.76%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROIC 8.76%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 300 400

1.3 Margins

  • TMDX has a Profit Margin of 31.43%. This is amongst the best in the industry. TMDX outperforms 98.91% of its industry peers.
  • Looking at the Operating Margin, with a value of 17.93%, TMDX belongs to the top of the industry, outperforming 88.59% of the companies in the same industry.
  • TMDX has a better Gross Margin (59.92%) than 61.41% of its industry peers.
  • TMDX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TMDX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
  • TMDX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TMDX has more shares outstanding
  • Compared to 1 year ago, TMDX has an improved debt to assets ratio.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • TMDX has an Altman-Z score of 5.07. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.07, TMDX is doing good in the industry, outperforming 78.80% of the companies in the same industry.
  • The Debt to FCF ratio of TMDX is 3.84, which is a good value as it means it would take TMDX, 3.84 years of fcf income to pay off all of its debts.
  • TMDX's Debt to FCF ratio of 3.84 is amongst the best of the industry. TMDX outperforms 80.43% of its industry peers.
  • A Debt/Equity ratio of 1.06 is on the high side and indicates that TMDX has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.06, TMDX is not doing good in the industry: 76.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Altman-Z 5.07
ROIC/WACC0.91
WACC9.66%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • TMDX has a Current Ratio of 7.14. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • TMDX's Current ratio of 7.14 is amongst the best of the industry. TMDX outperforms 86.41% of its industry peers.
  • TMDX has a Quick Ratio of 6.59. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TMDX (6.59) is better than 88.04% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 6.59
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TMDX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 178.22% over the past year.
  • Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 37.13%.
  • The Revenue has been growing by 88.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%

3.2 Future

  • Based on estimates for the next years, TMDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.03% on average per year.
  • Based on estimates for the next years, TMDX will show a quite strong growth in Revenue. The Revenue will grow by 17.79% on average per year.
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

4

4. TMDX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 40.42, the valuation of TMDX can be described as expensive.
  • Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 70.11% of the companies in the same industry.
  • TMDX is valuated expensively when we compare the Price/Earnings ratio to 25.79, which is the current average of the S&P500 Index.
  • TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 43.44.
  • 67.93% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
  • TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 40.42
Fwd PE 43.44
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 70.11% of the companies listed in the same industry.
  • TMDX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 78.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 29.17
EV/EBITDA 28.78
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • TMDX has a very decent profitability rating, which may justify a higher PE ratio.
  • TMDX's earnings are expected to grow with 18.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y18.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMDX Dividend Analysis

5.1 Amount

  • No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMDX Fundamentals: All Metrics, Ratios and Statistics

TRANSMEDICS GROUP INC

NASDAQ:TMDX (3/19/2026, 11:45:08 AM)

113.59

+0.38 (+0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners111.11%
Inst Owner Change-1.83%
Ins Owners2.99%
Ins Owner Change1.41%
Market Cap3.90B
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Analysts83
Price Target148.92 (31.1%)
Short Float %25.53%
Short Ratio10.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.66%
Min EPS beat(2)32.92%
Max EPS beat(2)84.39%
EPS beat(4)4
Avg EPS beat(4)96.18%
Min EPS beat(4)32.92%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)170.32%
EPS beat(12)10
Avg EPS beat(12)118.73%
EPS beat(16)13
Avg EPS beat(16)92.69%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)1.22%
Revenue beat(4)3
Avg Revenue beat(4)4.11%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)5.48%
Revenue beat(12)10
Avg Revenue beat(12)10.09%
Revenue beat(16)14
Avg Revenue beat(16)16.58%
PT rev (1m)0%
PT rev (3m)1.1%
EPS NQ rev (1m)-9.93%
EPS NQ rev (3m)-8.87%
EPS NY rev (1m)-11.51%
EPS NY rev (3m)-10.81%
Revenue NQ rev (1m)1.63%
Revenue NQ rev (3m)1.63%
Revenue NY rev (1m)1.77%
Revenue NY rev (3m)1.79%
Valuation
Industry RankSector Rank
PE 40.42
Fwd PE 43.44
P/S 6.43
P/FCF 29.17
P/OCF 20.2
P/B 8.24
P/tB 8.48
EV/EBITDA 28.78
EPS(TTM)2.81
EY2.47%
EPS(NY)2.61
Fwd EY2.3%
FCF(TTM)3.89
FCFY3.43%
OCF(TTM)5.62
OCFY4.95%
SpS17.65
BVpS13.79
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.53
Profitability
Industry RankSector Rank
ROA 17.81%
ROE 40.22%
ROCE 11.09%
ROIC 8.76%
ROICexc 17.48%
ROICexgc 17.98%
OM 17.93%
PM (TTM) 31.43%
GM 59.92%
FCFM 22.06%
ROA(3y)6.23%
ROA(5y)-5.44%
ROE(3y)12.5%
ROE(5y)-9.39%
ROIC(3y)4.27%
ROIC(5y)N/A
ROICexc(3y)8.3%
ROICexc(5y)N/A
ROICexgc(3y)8.55%
ROICexgc(5y)N/A
ROCE(3y)5.4%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.98%
GM growth 5Y-1.58%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.06
Debt/FCF 3.84
Debt/EBITDA 3.7
Cap/Depr 217.96%
Cap/Sales 9.79%
Interest Coverage 10.15
Cash Conversion 142.04%
Profit Quality 70.2%
Current Ratio 7.14
Quick Ratio 6.59
Altman-Z 5.07
F-Score7
WACC9.66%
ROIC/WACC0.91
Cap/Depr(3y)910.54%
Cap/Depr(5y)653.45%
Cap/Sales(3y)34%
Cap/Sales(5y)25.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)178.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%178.95%
EPS Next Y-6.95%
EPS Next 2Y15.67%
EPS Next 3Y18.54%
EPS Next 5Y12.03%
Revenue 1Y (TTM)37.13%
Revenue growth 3Y86.42%
Revenue growth 5Y88.21%
Sales Q2Q%32.18%
Revenue Next Year22.69%
Revenue Next 2Y20.67%
Revenue Next 3Y18.6%
Revenue Next 5Y17.79%
EBIT growth 1Y189.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.48%
EBIT Next 3Y45.75%
EBIT Next 5Y46.88%
FCF growth 1Y265.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y295.14%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSMEDICS GROUP INC / TMDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to TMDX.


Can you provide the valuation status for TRANSMEDICS GROUP INC?

ChartMill assigns a valuation rating of 4 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.


How profitable is TRANSMEDICS GROUP INC (TMDX) stock?

TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 6 / 10.


How financially healthy is TRANSMEDICS GROUP INC?

The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.